Pyxis Oncology, Inc.
PYXS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $2,820 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $2,820 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $17,808 | $17,133 | $17,044 | $14,024 |
| G&A Expenses | $5,653 | $5,437 | $5,870 | $5,081 |
| SG&A Expenses | $4,969 | $5,437 | $5,870 | $5,081 |
| Sales & Mktg Exp. | -$684 | $0 | $0 | $0 |
| Other Operating Expenses | $684 | $0 | $0 | $20,964 |
| Operating Expenses | $23,461 | $22,570 | $22,914 | $40,069 |
| Operating Income | -$23,461 | -$19,750 | -$22,914 | -$40,069 |
| % Margin | – | -700.4% | – | – |
| Other Income/Exp. Net | $1,458 | $1,679 | $1,756 | $2,334 |
| Pre-Tax Income | -$22,003 | -$18,071 | -$21,158 | -$37,735 |
| Tax Expense | $0 | $283 | $0 | -$2,164 |
| Net Income | -$22,003 | -$18,354 | -$21,158 | -$35,571 |
| % Margin | – | -650.9% | – | – |
| EPS | -0.35 | -0.3 | -0.35 | -0.58 |
| % Growth | -16.7% | 14.3% | 39.7% | – |
| EPS Diluted | -0.35 | -0.3 | -0.35 | -0.58 |
| Weighted Avg Shares Out | 62,557 | 61,919 | 61,049 | 60,715 |
| Weighted Avg Shares Out Dil | 62,557 | 61,919 | 61,049 | 60,715 |
| Supplemental Information | – | – | – | – |
| Interest Income | $774 | $995 | $1,241 | $1,620 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $535 | $535 | $552 | $550 |
| EBITDA | -$21,468 | -$19,215 | -$22,362 | -$18,555 |
| % Margin | – | -681.4% | – | – |